YTHomo sapiens (Human)Cancer cell line
Also known as: YT-0
YT Cell Line
Quick Overview
YT is a natural killer cell line derived from a patient with acute lymphoblastic lymphoma.
Detailed Summary
Research Applications
Key Characteristics
Basic Information
| Database ID | CVCL_1797 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Pericardial effusion[UBERON:UBERON_0002409] |
Disease Information
| Disease | Natural killer cell lymphoblastic leukemia/lymphoma |
|---|
DepMap Information
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Publications
Pan-cancer proteomic map of 949 human cell lines.";
Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Cancer Cell 40:835-849.e8(2022).
The LL-100 panel: 100 cell lines for blood cancer studies.";
MacLeod R.A.F., Nagel S., Steube K.G., Uphoff C.C., Drexler H.G.
Sci. Rep. 9:8218-8218(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
Activating mutations of STAT5B and STAT3 in lymphomas derived from gammadelta-T or NK cells.
de Leval L., McKeithan T.W., Chan W.-C.
Nat. Commun. 6:6025.1-6025.12(2015).
Natural killer cell lymphoma shares strikingly similar molecular features with a group of non-hepatosplenic gammadelta T-cell lymphoma and is highly sensitive to a novel aurora kinase A inhibitor in vitro.
Sng I., Liu X., Loughran T.P. Jr., Armitage J.O., Chan W.-C.
Leukemia 25:348-358(2011).
Detection of EBV, HBV, HCV, HIV-1, HTLV-I and -II, and SMRV in human and other primate cell lines.
Uphoff C.C., Denkmann S.A., Steube K.G., Drexler H.G.
J. Biomed. Biotechnol. 2010:904767.1-904767.23(2010).
Signatures of mutation and selection in the cancer genome.";
Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Nature 463:893-898(2010).
Genomic analyses reveal global functional alterations that promote tumor growth and novel tumor suppressor genes in natural killer-cell malignancies.
Tsui I.F.L., Ali H.H., Shimizu N., Au W.Y., Lam W.L., Chan W.-C.
Leukemia 23:1139-1151(2009).
Alterations in ATR in nasal NK/T-cell lymphoma and chronic active Epstein-Barr virus infection.
Liu A., Takakuwa T., Luo W.-J., Fujita S., Aozasa K.
Cancer Sci. 97:605-610(2006).
JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders.
Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.
Leukemia 20:471-476(2006).
Malignant hematopoietic cell lines: in vitro models for the study of natural killer cell leukemia-lymphoma.
Drexler H.G., Matsuo Y.
Leukemia 14:777-782(2000).
PTEN gene alterations in lymphoid neoplasms.";
Sakai A., Thieblemont C., Wellmann A., Jaffe E.S., Raffeld M.
Blood 92:3410-3415(1998).
Interleukin 2 high-affinity receptor expression requires two distinct binding proteins.
Teshigawara K., Wang H.-M., Kato K., Smith K.A.
J. Exp. Med. 165:223-238(1987).
TCGF (IL 2)-receptor inducing factor(s). I. Regulation of IL 2 receptor on a natural killer-like cell line (YT cells).
Takigawa M., Sasaki M.S., Minato N., Tsudo M., Uchiyama T., Maeda M.
J. Immunol. 134:1623-1630(1985).
Detection of Epstein-Barr virus genome in natural-killer-like cell line, YT.
Yamaguchi N.
Leukemia 6:136-141(1992).
The leukemia-lymphoma cell line factsbook.";
Drexler H.G.
(In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).